trial

A Prospective, Open-ended, Multi-center Study of Schizophrenia Patients Switching to Zolodine

NCTId NCT04975035
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Terminated
Enrollment 200 (actual)
Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University
Primary completion 2012-07-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Terminated
Enrollment
200 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-01-01
Primary completion
2012-07-01
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Zolodine

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityLead Sponsor

Sites

0 total

Linked catalysts

1
A Prospective, Open-ended, Multi-center Study of Schizophrenia Patients Switchin — primary completion2012-07-01

Facts & assertions

4 sourced
Enrollment
200
Phase
PHASE1,PHASE2
Primary Completion Date
2012-07-01
Status
TERMINATED
relationships
The graph out of here
drug
Zolodine
drug
lead_sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
company
indication
Schizophrenia
indication
Schizophrenia
indication